Madrigal Pharmaceuticals Inc

MDGL

Company Profile

  • Business description

    Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

  • Contact

    200 Barr Harbor Drive
    Suite 200, Four Tower Bridge
    West ConshohockenPA19428
    USA

    T: +1 267 824-2827

    E: [email protected]

    https://www.madrigalpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    528

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,779.006.000.07%
CAC 407,665.9125.64-0.33%
DAX 4023,909.61123.61-0.51%
Dow JONES (US)44,094.77275.500.63%
FTSE 1008,760.9637.95-0.43%
HKSE24,072.28211.87-0.87%
NASDAQ20,369.7396.270.47%
Nikkei 22540,019.94467.45-1.15%
NZX 50 Index12,646.5643.740.35%
S&P 5006,204.9531.880.52%
S&P/ASX 2008,548.506.200.07%
SSE Composite Index3,444.4320.200.59%

Market Movers